HOME2019-03-11T17:27:49+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Meet Paula Scurfield, one of the PD-MitoQUANT PPI volunteers

March 31st, 2020|

The public, including patients, can and should be involved in all aspects of research, including study design, communication, and ethics. Patients bring unique knowledge and skills to projects, which can improve the quality of research. The Innovative Medicines Initiative encourages public and patient involvement (PPI) in all of its projects. [...]

Richard Campbell, Parkinson’s UK volunteer, blogs about his involvement in PD-MitoQUANT

March 25th, 2020|

PD-MitoQUANT is fortunate to have two people with Parkinson’s, Richard Campbell and Paula Scurfield, involved in the project through our patient advocacy partner Parkinson’s UK (www.parkinsons.org.uk). Recently, Richard wrote a blog entitled “Getting involved in an international research project on Parkinson’s”. "Paula Scurfield and I are part of the Parkinson’s [...]

PD-MitoQUANT study published in Scientific Reports by researchers at CNRS

March 20th, 2020|

Congratulations to our partners at the Centre National de la Recherche Scientifique (CNRS) for their March 17, 2020, open-access paper published in Scientific Reports. The paper entitled "The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding" was authored by Josquin Courte, Luc Bousset, Ysander [...]

Read more